Trials / Completed
CompletedNCT00546533
Study Evaluating the Efficacy and Safety of Etanercept
Open-Label Evaluation Of The Efficacy And Safety Of Etanercept In Patients With Active Rheumatoid Arthritis (RA)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of etanercept 25 mg administered subcutaneously twice-weekly for 12 weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or inappropriate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept |
Timeline
- Start date
- 2003-01-01
- Completion
- 2005-02-01
- First posted
- 2007-10-19
- Last updated
- 2007-10-19
Source: ClinicalTrials.gov record NCT00546533. Inclusion in this directory is not an endorsement.